Differential Diagnosis, Clinical Features, and Prognosis of Multiple Sclerosis

  • Michael J. Olek
Part of the Current Clinical Neurology book series (CCNEU)

Abstract

The diagnosis and prognosis of multiple sclerosis (MS) has changed dramatically over the years from the first descriptions from St. Lidwina of Schiedam (1380–1433) and Augustus D’Este (grandson of George III) between 1822 and 1848 to the pathological descriptions of Cruveilhier (1829–1842) and Carswell (1838). Serious study and synthesis of clinical and pathological human MS began with the work of Jean Martin Charcot at the Salpetriere in Paris in the last three decades of the 19th century. Recently, there has been a trend to classify MS as an immune-mediated demyelinating disease of the central nervous system (CNS). This classification is useful as a diagnostic tool, as demonstrated by Schumacher (1962) and Poser (1983). The new diagnostic criteria (1), which is discussed in detail in the remainder of this chapter, has changed the diagnosis, prognosis, and treatment of MS.

Keywords

Depression Corticosteroid Dementia Carbamazepine Fluoxetine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.PubMedCrossRefGoogle Scholar
  2. 2.
    Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965;122:552–568.CrossRefGoogle Scholar
  3. 3.
    Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–231.PubMedCrossRefGoogle Scholar
  4. 4.
    Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;12:2059–2069.CrossRefGoogle Scholar
  5. 5.
    Tintore M, Rovira A, Martiniez MJ, et al. Isolated demyelinating syndrome: comparison of different MRI criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000;1:702–706.Google Scholar
  6. 6.
    Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–285.PubMedCrossRefGoogle Scholar
  7. 7.
    Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 1991;114(Pt 2):1013–1023.PubMedCrossRefGoogle Scholar
  8. 8.
    Offenbacher H, Fazekas F, Schmidt R, et al. Assessment of MRI criteria for a diagnosis of MS. Neurology 1993;43:905.PubMedGoogle Scholar
  9. 9.
    Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632–2637.PubMedGoogle Scholar
  10. 10.
    Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180.PubMedGoogle Scholar
  11. 11.
    Lee KH, Hashimoto SA, Hooge JP, et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1991;41:657.PubMedGoogle Scholar
  12. 12.
    Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116(pt 1):135–146.PubMedCrossRefGoogle Scholar
  13. 13.
    Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635.PubMedGoogle Scholar
  14. 14.
    Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993; 116(pt 5):1077.PubMedCrossRefGoogle Scholar
  15. 15.
    Tortorella C, Codella M, Rocca MA, et al. Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging. J Neurol 1999;246:689.PubMedCrossRefGoogle Scholar
  16. 16.
    Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76.PubMedCrossRefGoogle Scholar
  17. 17.
    Rudick RA, Whitaker JN. Cerebrospinal fluid tests for multiple sclerosis. In: Scheinberg P, ed. Neurology/Neurosurgery Update Series, Vol. 7. CPEC, Princeton, NJ, 1987, p 1.Google Scholar
  18. 18.
    Avasarala JR, Cross AH, Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001;58:2044.PubMedCrossRefGoogle Scholar
  19. 19.
    McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 1990;113(pt 5):1269.PubMedCrossRefGoogle Scholar
  20. 20.
    Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1720.PubMedGoogle Scholar
  21. 21.
    Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327.PubMedCrossRefGoogle Scholar
  22. 22.
    Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344:319.PubMedCrossRefGoogle Scholar
  23. 23.
    Hernan MA, Zhang SM, Lipworth L, et al. Multiple sclerosis and age at infection with common viruses. Epidemiology 2001;12:301.PubMedCrossRefGoogle Scholar
  24. 24.
    Marrie RA, Wolfson C, Sturkenboom MC, et al. Multiple sclerosis and antecedent infections: a case-control study. Neurology 2000;54:2307.PubMedGoogle Scholar
  25. 25.
    Wandinger K, Jabs W, Siekhaus A, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000;55:178.PubMedGoogle Scholar
  26. 26.
    Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001;286:3083.PubMedCrossRefGoogle Scholar
  27. 27.
    Sadovnick AD, Armstrong H, Rice GP, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993;33:281.PubMedCrossRefGoogle Scholar
  28. 28.
    Sawcer S, Jones HB, Feakes R, et al. A genomic screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996;13:464–468.PubMedCrossRefGoogle Scholar
  29. 29.
    The Multiple Sclerosis Genetics group. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. Nat Genet 1996;13:469–471.CrossRefGoogle Scholar
  30. 30.
    Ebers GC, Kukay K, Bulman DE, et al. A full genomic search in multiple sclerosis. Nat Genet 1996; 13:472–476.PubMedCrossRefGoogle Scholar
  31. 31.
    The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 1997;49:1404–1413.Google Scholar
  32. 32.
    Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995;45:244.PubMedGoogle Scholar
  33. 33.
    Rao SM, Reingold SC, Ron MA, et al. Workshop on Neurobehavioral Disorders in Multiple Sclerosis. Diagnosis, underlying disease, natural history, and therapeutic intervention, Bergamo, Italy, June 25–27, 1992. Arch Neurol 1993;50:658.PubMedGoogle Scholar
  34. 34.
    Mohr DC, Goodkin DE, Gatto N, Van der Wende J. Depression, coping and level of neurological impairment in multiple sclerosis. Mult Scler 1997;3:254.PubMedCrossRefGoogle Scholar
  35. 35.
    Olafsson E, Benedikz J, Hauser WA. Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia 1999;40:745.PubMedCrossRefGoogle Scholar
  36. 36.
    Nyquist PA, Cascino GD, Rodriguez M. Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minn, 1990–1998. Mayo Clin Proc 2001;76:983.PubMedCrossRefGoogle Scholar
  37. 37.
    Bakshi R, Miletich RS, Henschel K, et al. Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology 1999;53:1151.PubMedGoogle Scholar
  38. 38.
    Hohol MJ, Guttmann CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997;54:1018.PubMedGoogle Scholar
  39. 39.
    Rao SM, Leo GJ, Haughton VM, et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989;39:161.PubMedGoogle Scholar
  40. 40.
    Franklin GM, Heaton RK, Nelson LM, et al. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurology 1988;38:1826.PubMedGoogle Scholar
  41. 41.
    Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158–164.PubMedCrossRefGoogle Scholar
  42. 42.
    McAlpine D, Compston A, Ebers G, et al. McAlpine’s Multiple Sclerosis (3rd ed). Churchill Livingstone, London, 1999.Google Scholar
  43. 43.
    Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993; 20:17.PubMedGoogle Scholar
  44. 44.
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–911.PubMedGoogle Scholar
  45. 45.
    Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994;36(Suppl):S6.PubMedCrossRefGoogle Scholar
  46. 46.
    Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116(Pt 1):117–134.PubMedCrossRefGoogle Scholar
  47. 47.
    Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871–882.PubMedCrossRefGoogle Scholar
  48. 48.
    Cohen JA, Cutter GR, Fischer JS, et al. Use of the MSFC as an outcome measure in a phase III clinical trial. Arch Neurol 2001;58:961–967.PubMedCrossRefGoogle Scholar
  49. 49.
    Kalkers NF, Bergers L, de Groot V, et al. Concurrent validity of the MSFC using MRI as a biological disease marker. Neurology 2001;56:215–219.PubMedGoogle Scholar
  50. 50.
    Damek DM, Shuster EA. Pregnancy and multiple sclerosis. Mayo Clin Proc 1997;72:977–989.PubMedGoogle Scholar
  51. 51.
    Confavreux C, Vukusic C, Adeleine P. Early clinical predictors and prognosis of irreversible disability in multiple sclerosis: an amnestic process. Brain 2003;126;770–782.PubMedCrossRefGoogle Scholar
  52. 52.
    Myhr KM, Riise T, Vedeler C, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001;7:59–65.PubMedGoogle Scholar
  53. 53.
    Scott TF, Schramke CJ, Novero J, Chieffe C. Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurology 2000;55:689–693.PubMedGoogle Scholar
  54. 54.
    Mandler RN, Davis LE, Jeffery DR, Kornfield M. Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993;34:162.PubMedCrossRefGoogle Scholar
  55. 55.
    Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60:848–853.PubMedGoogle Scholar
  56. 56.
    Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: Intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993;33:18–27.PubMedCrossRefGoogle Scholar
  57. 57.
    Johnson MD, Lavin P, Whetsell WO Jr. Fulminant monophasic multiple sclerosis, Marburg’s type. J Neurol Neurosurg Psychiatry 1990;53:918–921.PubMedGoogle Scholar
  58. 58.
    Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis—clinical and immunologic studies. N Engl J Med 1984;310:137–141.PubMedCrossRefGoogle Scholar
  59. 59.
    Olek MJ, Dawson DM. Multiple Sclerosis and Other Inflammatory Demyelinating Diseases of the Central Nervous System. Butterworth-Heinemann, 1999.Google Scholar
  60. 60.
    Kesselring J, Miller DH, Robb SA, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990;113(Pt 2):291–302.PubMedCrossRefGoogle Scholar
  61. 61.
    Lieberman AP, Grossman RI, Lavi E. Case of the month: April 1997—a 32-year-old man with mental status changes and a severe occipital headache. Brain Pathol 1998;8:229.PubMedGoogle Scholar
  62. 62.
    Knebusch M, Strassburg HM, Reiners K. Acute transverse myelitis in childhood: nine cases and review of the literature. Dev Med Child Neurol 1998;40:631.PubMedCrossRefGoogle Scholar
  63. 63.
    Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology 1992;42:250–252.PubMedGoogle Scholar
  64. 64.
    de Fraiture DM, Sie TH, Boezeman EH, Haanen HC. Cerebellitis as an uncommon complication of infectious mononucleosis. Nether J Med 1997;51:79.CrossRefGoogle Scholar
  65. 65.
    Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47.PubMedCrossRefGoogle Scholar
  66. 66.
    Tintore M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003;60:27.PubMedCrossRefGoogle Scholar
  67. 67.
    Berger TB, Rubner P, Schautler F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:107–109.CrossRefGoogle Scholar
  68. 68.
    Paty D, Studney D, Redekop K, Lublin F. MS COSTAR: a computerized patient record adapted for clinical research purposes. Ann Neurol 1994;36:S134.PubMedCrossRefGoogle Scholar
  69. 69.
    Studney D, Lublin F, Marcucci L, et al. MS COSTAR: a computerized patient record adapted for clinical research purposes. J Neurol Rehab 1993;7:145.Google Scholar
  70. 70.
    Sadovnick AD, Baird PA, Ward RH, et al. Multiple sclerosis: updated risks for relatives. Am J Med Genet 1988;29:533–541.PubMedCrossRefGoogle Scholar
  71. 71.
    O’Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998;121:495–503.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Michael J. Olek
    • 1
  1. 1.Multiple Sclerosis Center, Department of NeurologyUniversity of CaliforniaIrvine

Personalised recommendations